Gilead Sciences Inc (NASDAQ:GILD)

70.00
Data as of Apr 17
 +0.72 / +1.04%
Today’s Change
46.70
Today|||52-Week Range
84.88
-6.79%
Year-to-Date
3 Reasons the Market Is Down on Gilead Sciences
Apr 18 / MotleyFool.com
Jim Cramer's Stop Trading: GILD KORS
Apr 15 / TheStreet.com
Jim Cramer: We're in the Grips of a Struggle
Apr 18 / TheStreet.com
Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for H...
Apr 15 / MotleyFool.com
Tech rally lifts Nasdaq off recent lows
Apr 18 / FT.com
Are Biotechs Bad Medicine for the S&P 500?
Apr 15 / MotleyFool.com
We're in the Grips of a Struggle
Apr 17 / TheStreet.com
Hard-to-Cure Patients May Benefit from Merck's HCV Drug - Analyst Blog
Apr 14 / Zacks.com
Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear
Apr 17 / MotleyFool.com
Positive Data on AbbVie's HCV Program - Analyst Blog
Apr 14 / Zacks.com
Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead
Apr 17 / MotleyFool.com
Markets Falling? Get Your Defense Ready
Apr 14 / Benzinga
Surprises Among the Leaders
Apr 17 / TheStreet.com
Is This the Answer to Expensive Hepatitis-C Cures?
Apr 14 / MotleyFool.com
Today's Top Performers In Drugs
Apr 17 / TheStreet.com
Gilead Bucks Biotech Trend Thanks to Sovaldi News - Analyst Blog
Apr 14 / Zacks.com
If This Biotech Drops Much Further I'm Going to Buy It!
Apr 17 / MotleyFool.com
Stocks bounce back...somewhat
Apr 14 / CNNMoney.com
Managers See Buys in Choppy Markets, Including Gilead, LinkedIn
Apr 17 / TheStreet.com
Encouraging Results on Gilead's Sovaldi - Analyst Blog
Apr 11 / Zacks.com
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Apr 17 / MotleyFool.com
Eight pricey stocks haunting the Nasdaq
Apr 11 / Fortune
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
Apr 17 / TheStreet.com
JPMorgan's Earnings Disaster Drops the Dow 100 Points
Apr 11 / MotleyFool.com
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Apr 16 / MotleyFool.com
US retailers fall after The Gap reports sales slide
Apr 11 / FT.com
3 Stocks to Get on Your Watchlist
Apr 16 / MotleyFool.com
Encouraging Data from Bristol-Myers - Analyst Blog
Apr 11 / Zacks.com
3 Stocks Reiterated As A Buy: EBAY, GS, GILD
Apr 16 / TheStreet.com
Stock Market News for April 11, 2014 - Market News
Apr 11 / Zacks.com
Johnson and Johnson Earnings Surprises With Blockbuster Potential
Apr 16 / MotleyFool.com
Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Apr 11 / Zacks.com
The S&P 500's 3 Biggest Biotech Losers of 2014
Apr 16 / MotleyFool.com
Merck Shouts "Me, Too!" But Will It Matter?
Apr 11 / MotleyFool.com
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data -...
Apr 16 / Zacks.com
Today's Biotech Stocks to Watch: AbbVie Inc., Enanta Pharmaceuticals Inc. and Gilead ...
Apr 11 / MotleyFool.com
3 Biotech Opportunities Following This Selloff
Apr 16 / MotleyFool.com
Tech stock rout continues in Asia
Apr 11 / CNNMoney.com
Why Gilead Sciences Inc. (GILD) Stock Might be a Great Pick - Tale of the Tape
Apr 16 / Zacks.com
Why Alexion Pharmaceuticals, Gilead Sciences, and Monster Beverage Corporation Are To...
Apr 10 / MotleyFool.com
Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog
Apr 15 / Zacks.com
Biotech stocks dumped in market rout
Apr 10 / FT.com
How Much Has Merck Shaken Up the Hepatitis C Race?
Apr 15 / MotleyFool.com
Gilead Announces Encouraging Sovaldi Data - Analyst Blog
Apr 10 / Zacks.com
Gilead Sciences Inc (GILD): Today's Featured Drugs Winner
Apr 15 / TheStreet.com
Merck Up on Encouraging HCV Data - Analyst Blog
Apr 10 / Zacks.com
Health Care Stocks: Check Out This Low-Cost Market Beater
Apr 15 / MotleyFool.com
Stunning Spending Growth Prediction for Hepatitis C
Apr 10 / MotleyFool.com
Biotech Bubble Bust: 2 Ways to Win
Apr 15 / MotleyFool.com
Gilead Sciences Inc. (GILD): New Analyst Report from Zacks Equity Research - Zacks Eq...
Apr 10 / Zacks.com

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.